A Review of Microbiota and Irritable Bowel Syndrome : Future in Therapies
Rodiño-Janeiro, Bruno K. (Hospital Universitari Vall d'Hebron)
Vicario Perez, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Alonso Cotoner, Carmen (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Pascua-García, Roberto (Servicio de Atención Primaria de Celanova (Orense, Galícia))
Santos, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Data:	2018
Resum:	Irritable bowel syndrome (IBS), one of the most frequent digestive disorders, is characterized by chronic and recurrent abdominal pain and altered bowel habit. The origin seems to be multifactorial and is still not well defined for the different subtypes. Genetic, epigenetic and sex-related modifications of the functioning of the nervous and immune-endocrine supersystems and regulation of brain-gut physiology and bile acid production and absorption are certainly involved. Acquired predisposition may act in conjunction with infectious, toxic, dietary and life event-related factors to enhance epithelial permeability and elicit mucosal microinflammation, immune activation and dysbiosis. Notably, strong evidence supports the role of bacterial, viral and parasitic infections in triggering IBS, and targeting microbiota seems promising in view of the positive response to microbiota-related therapies in some patients. However, the lack of highly predictive diagnostic biomarkers and the complexity and heterogeneity of IBS patients make management difficult and unsatisfactory in many cases, reducing patient health-related quality of life and increasing the sanitary burden. This article reviews specific alterations and interventions targeting the gut microbiota in IBS, including prebiotics, probiotics, synbiotics, non-absorbable antibiotics, diets, fecal transplantation and other potential future approaches useful for the diagnosis, prevention and treatment of IBS.
Ajuts:	Instituto de Salud Carlos III CD15-00010 Instituto de Salud Carlos III MV17-00043 Instituto de Salud Carlos III CPII16-00031 Instituto de Salud Carlos III PI16-00583 Instituto de Salud Carlos III PI15-00301 Instituto de Salud Carlos III PI14-00994
Nota:	Altres ajuts: Supported in part by Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD): CB06/04/0021 (MV, CA& JS). No funding or sponsorship was received for covering the expenses of publication of this article.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Diet ; FODMAP ; Irritable bowel syndrome ; Microbiota ; Non-absorbable antibiotic ; Prebiotic ; Probiotic ; Synbiotic ; Treatment
Publicat a:	Advances in Therapy, Vol. 35 (march 2018) , p. 289-310, ISSN 1865-8652

DOI: 10.1007/s12325-018-0673-5
PMID: 29498019

22 p, 609.1 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats